Skip to main content
SpringerLink
Log in

Behandlung der multiplen Sklerose

  • Chapter
Demyelinisierende Erkrankungen

  • 45 Accesses

Zusammenfassung

Die Therapie der multiplen Sklerose hat sich in den letzten Jahren grundlegend gewandelt. Basierend auf dem wachsenden immunpathogenetischen Verständnis der Erkrankung entstand mit Hilfe der modernen Biotechnologie ein wachsendes Arsenal potenzieller Therapeutika, die sich im Sinne einer „Spezifitätspyramide“ von genereller Immunsuppression bis hin zur spezifischen Blockierung von T-Zell-Rezeptor-Peptid-MHC-Komplexen (major histocompatibility complex) erstrecken. Während verschiedene neue Therapeutika nach eingehender klinischer Prüfung zugelassen wurden und inzwischen in der Routinebehandlung der MS etabliert sind (Beta-Interferone, Glatirameracetat, Mitoxantron), befindet sich eine große Zahl neuer Therapien derzeit in der Entwicklung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Wiendl H, Melms A, Hohlfeld R (2003) Multiple Sklerose and andere demyelinisierende Erkrankungen. In: Brandt T, Dichgans J, Diener HC (eds) Therapie and Verlauf neurologischer Erkrankungen, 4. Auflage. Kohlhammer (im Druck)

    Google Scholar 

  2. Mäurer M, Rieckmann P (2000) What is the potential of combination therapy in MS. BioDrugs

    Google Scholar 

  3. Gold R, Buttgereit F, Toyka KV (2001) Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117:1–8

    Article  CAS  PubMed  Google Scholar 

  4. Schmidt J, Gold R, Schonrock L, Zettl UK, Hartung HP, Toyka KV (2000) T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 123:1431–1441

    Article  PubMed  Google Scholar 

  5. Barnes MP, Bateman DE, Cleland PG et al. (1985) Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 48: 157–159

    Article  CAS  PubMed  Google Scholar 

  6. Milligan NM, Newcombe R, Compston DA (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 50:511–516

    Article  CAS  PubMed  Google Scholar 

  7. Beck RW, Cleary PA, Trobe JD et al. (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329:1764–1769

    Article  CAS  PubMed  Google Scholar 

  8. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J (1998) Double-blind, randomized, plazebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51:529–534

    Article  CAS  PubMed  Google Scholar 

  9. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52:1479–1484

    Article  CAS  PubMed  Google Scholar 

  10. Grauer O, Offenhausser M, Schmidt J, Toyka KV, Gold R (2001) Glucocorticosteroid therapy in optic neuritis and multiple sclerosis. Evidence from clinical studies and practical recommendations. Nervenarzt 72:577–589

    Article  CAS  PubMed  Google Scholar 

  11. Miller DH, Thompson AJ, Morrissey SP et al. (1992) High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 55:450–453

    Article  CAS  PubMed  Google Scholar 

  12. Beck RW (1997) Clinically definite multiple sclerosis following optic neuritis. Ann Neurol 42:815–816

    Article  CAS  PubMed  Google Scholar 

  13. Beck RW (1995) The optic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol 113:136–137

    Article  CAS  PubMed  Google Scholar 

  14. Goodkin DE, Kinkel RP, Weinstock-Guttman B et al. (1998) A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51:239–245

    Article  CAS  PubMed  Google Scholar 

  15. Cazzato G, Mesiano T, Antonello R et al. (1995) Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 35: 193–198

    Article  CAS  PubMed  Google Scholar 

  16. Kümpfel T, Schumann E, Then Bergh F et al. (2001) Monthly high-dose methylprednisolone pulse therapy in patients with multiple sclerosis: an MRI controlled study with single crossover design. Neurology (56)A76 (Abstract)

    Google Scholar 

  17. Zivadinov R, Rudick RA, De Masi R et al. (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57:1239–1247

    Article  CAS  PubMed  Google Scholar 

  18. van Buskirk C, Poffenbarger AL, Capriles LF, Idea BV (1964) Treatment of multiple sclerosis with intrathecal steroids. Neurology 14:595–597

    Article  Google Scholar 

  19. Rohrbach E, Kappos L, Städt D et al. (1988) Intrathecal versus oral corticosteroid therapy of spinal symptoms in multiple sclerosis: a double-blind controlled trial. Neurology 38:256

    Google Scholar 

  20. Beck RW, Cleary PA, Anderson MM Jr et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326:581–588

    Article  CAS  PubMed  Google Scholar 

  21. Oliveri RL, Valentino P, Russo C et al. (1998) Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 50:1833–1836

    Article  CAS  PubMed  Google Scholar 

  22. Panitch HS, Hirsch RL, Schindler J, Johnson KP (1987) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37:1097–1102

    Article  CAS  PubMed  Google Scholar 

  23. Durelli L, Bongioanni MR, Cavallo R et al. (1994) Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 44:406–413

    Article  CAS  PubMed  Google Scholar 

  24. Jacobs L, Salazar AM, Herndon R et al. (1987) Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study. Arch Neurol 44:589–595

    Article  CAS  PubMed  Google Scholar 

  25. Jacobs L, Johnson KP (1994) A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol 51:1245–1252

    Article  CAS  PubMed  Google Scholar 

  26. Stone LA, Frank JA, Albert PS et al. (1995) The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 37:611–619

    Article  CAS  PubMed  Google Scholar 

  27. Arnason BG, Dayal A, Qu ZX, Jensen MA, Genc K, Reder AT (1996) Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol 18:125–148

    Article  CAS  PubMed  Google Scholar 

  28. Wandinger KP, Sturzebecher CS, Bielekova B et al. (2001) Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 50:349–357

    Article  CAS  PubMed  Google Scholar 

  29. Walther EU, Hohlfeld R (1999) Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 53:1622–1627

    Article  CAS  PubMed  Google Scholar 

  30. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43:655–661

    Article  Google Scholar 

  31. IFNB Multiple Sclerosis Study Group (1995) Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 45:1277–1285

    Article  Google Scholar 

  32. Jacobs LD, Cookfair DL, Rudick RA et al. (1996) Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285–294

    Article  CAS  PubMed  Google Scholar 

  33. PRISMS Study Group (1998) A randomized, placebo-controlled, double-blind study of interferon-beta la in relapsing-remitting multiple sclerosis. Lancet 352: 1498–1504

    Article  Google Scholar 

  34. The Once Weekly Interferon for MS Study Group (1999) Evidence of interferon beta-la dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology 53:679–686

    Article  Google Scholar 

  35. European Study Group on Interferon Beta-lb in Secondary Progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-lb in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-lb in secondary progressive MS. Lancet 352:1491–1497

    Article  Google Scholar 

  36. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F (2001) Final analysis of the European multicenter trial on IFN beta-lb in secondary-progressive MS. Neurology 57:1969–1975

    Article  CAS  PubMed  Google Scholar 

  37. Jacobs LD, Beck RW, Simon JH et al. (2000) Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904

    Article  CAS  PubMed  Google Scholar 

  38. Comi G, Filippi M, Barkhof F et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582

    Article  CAS  PubMed  Google Scholar 

  39. Paty DW, Li DK (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43:662–667

    Article  CAS  PubMed  Google Scholar 

  40. PRISMS Study Group (2001) PRISMS-4: Long-term efficacy of interferonbeta-la in relapsing MS. Neurology 56:1628–1636

    Article  Google Scholar 

  41. Rice GP, Incorvaia B, Munari L et al. (2001) Interferon in relapsing-remitting multiple sclerosis (Cochrane Review). Cochrane Database Syst Rev 4: Update Software

    Google Scholar 

  42. Goodin DS, Frohman EM, Garmany GP Jr et al. (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169–178

    Article  CAS  PubMed  Google Scholar 

  43. Goodkin DE, and the NASPMS Study Group (2000) The North American Study of interferon beta-lb in secondary progressive multiple sclerosis. 52nd Annual Meeting of the American Academy of Neurology, San Diego, CA, Abstract LBN.002

    Google Scholar 

  44. SPECTRIMS Study Group (2001) Randomized controlled trial of interferonbeta-la in secondary progressive MS: Clinical results. Neurology 56:1496–1504

    Article  Google Scholar 

  45. Li DK, Zhao GJ, Paty DW (2001) Randomized controlled trial of interferonbeta-la in secondary progressive MS: MRI results. Neurology 56:1505–1513

    Article  CAS  PubMed  Google Scholar 

  46. Cohen JA, Cutter GR, Fischer JS et al. (2002) Benefit of interferon beta-la on MSFC progression in secondary progressive MS. Neurology 59:679–687

    Article  CAS  PubMed  Google Scholar 

  47. Anonymus (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 49:1404–1413

    Article  Google Scholar 

  48. Morrissey SP, Miller DH, Kendall BE et al. (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116:135–146

    Article  PubMed  Google Scholar 

  49. O’Riordan JI, Thompson AJ, Kingsley DP et al. (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121 (Pt 3):495–503

    Article  PubMed  Google Scholar 

  50. Sailer M, O’Riordan JI, Thompson AJ et al. (1999) Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 52:599–606

    Article  CAS  PubMed  Google Scholar 

  51. Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158–164

    Article  PubMed  Google Scholar 

  52. Mäurer M, Gold R, Toyka KV, Rieckmann P (2001) Behandlung der schubförmigen Multiplen Sklerose mit rekombinanten Interferon-ß-Präparaten: Aspekte zur Pharmakologie and Dosierung. Nervenarzt 72:108–116

    Article  PubMed  Google Scholar 

  53. Clanet M, Radue EW, Kappos L et al. (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-la in relapsing MS. Neurology 59:1507–1517

    Article  CAS  PubMed  Google Scholar 

  54. Panitch H, Goodin DS, Francis G et al. (2002) Randomized, comparative study of interferon beta-la treatment regimes in MS: The Evidence Trial. Neurology 59:1496–1506

    Article  CAS  PubMed  Google Scholar 

  55. Durelli L, Verdun E, Barbero P et al. (2002) Every-other-day interferon beta-lb versus once-weekly interferon beta-la for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453–1460

    Article  CAS  PubMed  Google Scholar 

  56. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP (2001) A prospective, open-label treatment trial to compare the effect of IFN beta-la (Avonex), IFN beta-lb (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Multiple Sclerosis 7:249353

    Google Scholar 

  57. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (2002) Immunmodulierende Stufentherapie der Multiplen Sklerose. 2. Ergänzung. Der Nervenarzt 2002 73(6):556–563

    Google Scholar 

  58. Ross C, Clemmesen KM, Svenson M et al. (2000) Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 48:706–712

    Article  CAS  PubMed  Google Scholar 

  59. Arnason BG, Dianzani F (1998) Correlation of the appearance of anti-interferon antibodies during treatment and dimunition of efficacy: summary of an International Workshop on Anti-Interferon Antibodies. J Interferon Cytokine Res 18:639–644

    Article  CAS  PubMed  Google Scholar 

  60. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M (1972) Protection against experimental allergic encephalomyelitis. Nature 240:564–566

    Article  CAS  PubMed  Google Scholar 

  61. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA (2000) Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105:967–976

    Article  CAS  PubMed  Google Scholar 

  62. Neuhaus O, Farina C, Yassouridis A et al. (2000) Multiple sclerosis: comparison of copolymer-l-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 97:7452–7457

    Article  CAS  PubMed  Google Scholar 

  63. Gran B, Tranquill LR, Chen M et al. (2000) Mechanisms of immunomodulation by glatiramer acetate. Neurology 55:1704–1714

    Article  CAS  PubMed  Google Scholar 

  64. Teitelbaum D, Arnon R, Sela M (1999) Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer-I. Proc Natl Acad Sci USA 96:3842–3847

    Article  CAS  PubMed  Google Scholar 

  65. Neuhaus O, Farina C, Wekerle H, Hohlfeld R (2001) Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56:702–708

    Article  CAS  PubMed  Google Scholar 

  66. Krogsgaard M, Wucherpfennig KW, Canella B et al. (2000) Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85–99 complex. J Exp Med 191:1395–1412

    Article  CAS  PubMed  Google Scholar 

  67. Kerschensteiner M, Gallmeier E, Behrens L et al. (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189:865–870

    Article  CAS  PubMed  Google Scholar 

  68. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H (2000) The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 107:161–166

    Article  CAS  PubMed  Google Scholar 

  69. Bornstein MB, Miller A, Slagle S et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317:408–414

    Article  CAS  PubMed  Google Scholar 

  70. Bornstein MB, Miller A, Slagle S et al. (1991) A plazebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41:533–539

    Article  CAS  PubMed  Google Scholar 

  71. Wolinsky JS, Narayana PA, and the PROMISE Study Group (2001) Characteristics at entry into the glatiramer acetate study of primary progressive multiple sclerosis: The PROMiSe Trial. J Neurol, p 248

    Google Scholar 

  72. Johnson KP, Brooks BR, Cohen JA et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268–1276

    Article  CAS  PubMed  Google Scholar 

  73. Mancardi GL, Sardanelli F, Parodi RC et al. (1998) Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 50:1127–1133

    Article  CAS  PubMed  Google Scholar 

  74. Johnson KP, Brooks BR, Cohen JA et al. (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50:701–708

    Article  CAS  PubMed  Google Scholar 

  75. Johnson KP, Brooks BR, Ford CC et al. (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 6:255–266

    CAS  PubMed  Google Scholar 

  76. Johnson KP, Brooks BR, Ford CC et al. (2002) Results of the long-term (eight-year) prospective, open-label trial of glatiramer acetate for relapsing multiple sclerosis. Neurology 58:A458, Suppl 453

    Google Scholar 

  77. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290–297

    Article  CAS  PubMed  Google Scholar 

  78. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology 57:731–733

    Article  CAS  PubMed  Google Scholar 

  79. Zwibel H (2001) Benefit of Copaxone demonstrated in patients with relapsing-remitting multiple sclerosis (RRMS) previously treated with interferon. J Neurol, p 248

    Google Scholar 

  80. Stangel M, Hartung HP, Marx P, Gold R (1998) Intravenous immunoglobulin treatment of neurological autoimmune disorders. J Neurol Sci 153:203–214

    Article  CAS  PubMed  Google Scholar 

  81. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755

    Article  CAS  PubMed  Google Scholar 

  82. Rodriguez M, Lennon VA (1990) Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 27:12–17

    Article  CAS  PubMed  Google Scholar 

  83. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 349:589–593

    Article  CAS  PubMed  Google Scholar 

  84. Achiron A, Gabbay U, Gilad R et al. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398–402

    Article  CAS  PubMed  Google Scholar 

  85. Sorensen PS, Wanscher B, Jensen CV et al. (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50: 1273–1281

    Article  CAS  PubMed  Google Scholar 

  86. Teksam M, Tali T, Kocer B, Isik S (2000) Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 42:885–889

    Article  CAS  PubMed  Google Scholar 

  87. Soelberg-Soerensen P (2001) ESIMS. European Charcot Foundation, Venice

    Google Scholar 

  88. Van Engelen BG, Hommes OR, Pinckers A, Cruysberg JR, Barkhof F, Rodriguez M (1992) Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis [letter]. Ann Neurol 32:834–835

    Article  PubMed  Google Scholar 

  89. Noseworthy JH, O’Brien PC, Weinshenker BG et al. (2000) IV immunoglobulin does not reverse established weakness in MS: A double-blind, placebo-controlled trial. Neurology 55:1135–1143

    Article  CAS  PubMed  Google Scholar 

  90. Noseworthy JH, O’Brien PC, Petterson TM et al. (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514–1522

    Article  CAS  PubMed  Google Scholar 

  91. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S (2000) Placebo-controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68:89–92

    Article  CAS  PubMed  Google Scholar 

  92. Stangel M, Hartung H-P (2002) IVIg bei Multipler Sklerose: Studien and Wirkmechanismen - ein Update. Der Nervenarzt 73(2):119–124

    Article  CAS  PubMed  Google Scholar 

  93. Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R (1996) Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 243: 25–28

    Article  CAS  PubMed  Google Scholar 

  94. Orvieto R, Achiron R, Rotstein Z, Noy S, Bar-Hava I, Achiron A (1999) Pregnancy and multiple sclerosis: a 2-year experience. Eur J Obstet Gynecol Re-prod Biol 82:191–194

    Article  CAS  Google Scholar 

  95. Haas J (2000) High dose IVIg in the post partum period for prevention of exacerbations in MS. Multiple Sclerosis 6:18–20

    Google Scholar 

  96. Multiple Sklerose Therapie Konsensus Gruppe (1999) Immunmodulierende Stufentherapie der Multiplen Sklerose. Nervenarzt 70:371–386

    Article  Google Scholar 

  97. Multiple Sklerose Therapie Konsensus Gruppe (2001) Immunmodulierende Stufentherapie der Multiplen Sklerose. 1. Ergänzung Dezember 2000. Nervenarzt 72:150–157

    Article  Google Scholar 

  98. Gonsette RE (1996) Mitoxantrone immunotherapy in multiple sclerosis. Mult Scler 1:329–332

    CAS  PubMed  Google Scholar 

  99. Edan G, Le Page E, Taurin G et al. (2001) Safety profile of mitoxantrone in a cohort of 293 multiple sclerosis patients. Neurology (56) (Abstract)

    Google Scholar 

  100. Cursiefen S, Flachenecker P, Rieckmann P, Toyka KV (1999) Mitoxantrone (Novantron) in therapy of severe multiple sclerosis. A retrospective study of 15 patients. Nervenarzt 70:723–731

    Article  CAS  PubMed  Google Scholar 

  101. Bastianello S, Pozzilli C, D’Andrea F et al. (1994) A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neu-rol Sci 21:266–270

    CAS  Google Scholar 

  102. Edan G, Miller D, Clanet M et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112–118

    Article  CAS  PubMed  Google Scholar 

  103. Millefiorini E, Gasperini C, Pozzilli C et al. (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244:153–159

    Article  CAS  PubMed  Google Scholar 

  104. Hartung H-P, Gonsette P, König N et al. (2002) A Phase 3 placebo-controlled, double-blind, randomised, multicentre trial of mitoxantrone in progressive multiple sclerosis. Lancet 360:2018–2025

    Article  PubMed  Google Scholar 

  105. Kappos L (1990) Immunsuppressive Therapie der multiplen Sklerose mit Cyclosporin A and Azathioprin. Springer, Heidelberg Berlin New York

    Book  Google Scholar 

  106. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW (1991) The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 41:20–25

    Article  CAS  PubMed  Google Scholar 

  107. Yudkin PL, Ellison GW, Ghezzi A et al. (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338:1051–1055

    Article  CAS  PubMed  Google Scholar 

  108. Palace J, Rothwell P (1997) New treatments and azathioprine in multiple sclerosis. Lancet 350:261

    Article  CAS  PubMed  Google Scholar 

  109. Milanese C, La Mantia L, Salmaggi A, Caputo D (2001) Azathioprine and interferon beta-lb treatment in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 70:413–414

    Article  CAS  PubMed  Google Scholar 

  110. Smith DR, Balashov KE, Hafler DA, Khoury SJ, Weiner HL (1997) Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 42:313–318

    Article  CAS  PubMed  Google Scholar 

  111. Anonymus (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 337:441–446

    Google Scholar 

  112. Weiner HL, Mackin GA, Orav EJ et al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43: 910–918

    Article  CAS  PubMed  Google Scholar 

  113. Mackin GA, Dawson DM, Hafler DA, Weiner HL (1992) Treatment of Multiple Sclerosis with cyclophosphamide. In: Rudick RA, Goodkin DE (eds) Treatment of Multiple Sclerosis - Trial Design, Results and Future Perspectives. Springer, London, pp 199–216

    Google Scholar 

  114. Noseworthy JH, Vandervoort MK, Penman M et al. (1991) Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 337:1540–1541

    Article  CAS  PubMed  Google Scholar 

  115. Gobbini MI, Smith ME, Richert ND, Frank JA, McFarland HF (1999) Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 99:142–149

    Article  CAS  PubMed  Google Scholar 

  116. Pette M, Hartung HP, Toyka KV (1994) Cyclophosphamid in der Therapie der chronisch progressiven Multiplen Sklerose. Kritische Analyse gegenwärtiger Studien. Nervenarzt 65:271–274

    CAS  PubMed  Google Scholar 

  117. Goodkin DE, Rudick RA, VanderBrug Medendorp S et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37:30–40

    Article  CAS  PubMed  Google Scholar 

  118. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Van Dyke C (1996) Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 47:1153–1157

    Article  CAS  PubMed  Google Scholar 

  119. Kappos L, Patzold U, Dommasch D et al. (1988) Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis - results of the German multicenter study. Ann Neurol 23:56–63

    Article  CAS  PubMed  Google Scholar 

  120. Rudge P, Koetsier JC, Mertin J et al. (1989) Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 52:559–565

    Article  CAS  PubMed  Google Scholar 

  121. Anonymus (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group. Ann Neurol 27:591–605

    Article  Google Scholar 

  122. Ahrens N, Salama A, Haas J (2001) Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 248:713–714

    Article  CAS  PubMed  Google Scholar 

  123. Barkhof F, Filippi M, Miller DH et al. (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 (Pt 11):2059–2069

    Article  PubMed  Google Scholar 

  124. Hohlfeld R, Wiendl H (2001) The ups and downs of multiple sclerosis therapeutics. Ann Neurol 49:281–284

    Article  CAS  PubMed  Google Scholar 

  125. Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems and perspectives. Brain 120:865–916

    Article  PubMed  Google Scholar 

  126. Weilbach FX, Gold R (1999) Disease modifying treatments for multiple sclerosis: what is on the horizon? CNS drug 11:133–157

    Article  CAS  Google Scholar 

  127. Wiendl H, Hohlfeld R (2002) Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16:183–200

    Article  CAS  PubMed  Google Scholar 

  128. Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR (2002) Multiple Sclerosis: Deeper Understanding of Its Pathogenesis Reveals New Targets for Therapy. Annu Rev Neurosci 25:491–505

    Article  CAS  PubMed  Google Scholar 

  129. National Multiple Sclerosis Society Homepage MS Aictfhttp://www.nationalmssociety.org/nmssupload/pdf/agents.pdf

  130. Tubridy N, Behan PO, Capildeo R et al. (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53:466–472

    Article  CAS  PubMed  Google Scholar 

  131. Miller D, Khan OA, Sheremata WA et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23

    Article  CAS  PubMed  Google Scholar 

  132. Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffmann RG (1985) Plasmapheresis in progressive MS. Neurology 35:614

    Article  CAS  PubMed  Google Scholar 

  133. Weiner HL, Dau PC, Khatri BO et al. (1989) Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 39:1143–1149

    Article  CAS  PubMed  Google Scholar 

  134. Weinshenker BG, O’Brien PC, Petterson TM et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886

    Article  CAS  PubMed  Google Scholar 

  135. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG (2002) Plasma exchange for severe attacks of CNS demyelination: Predictors of response. Neurology 58:143–146

    Article  CAS  PubMed  Google Scholar 

  136. Kraft GH, Bowen JD, Cui JY, Nash RA (2002) Clinical application of autologous stem cell transplantation in severe multiple sclerosis treated with high-dose immunosuppressive therapy. Neurology 58(Suppl 163):A166

    Google Scholar 

  137. Mancardi GL, Saccardi R, Filippi M et al. (2001) Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57:62–68

    Article  CAS  PubMed  Google Scholar 

  138. Fassas A, Passweg JR, Anagnostopoulos A et al. (2002) Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249:1088–1097

    Article  CAS  PubMed  Google Scholar 

  139. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344:9–13

    Article  CAS  PubMed  Google Scholar 

  140. Rice GP, Filippi M, Comi G (2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54:1145–1155

    Article  CAS  PubMed  Google Scholar 

  141. Filippi M, Rovaris M, Rice GP et al. (2000) The effect of cladribine on T(1) `black hole’ changes in progressive MS. J Neurol Sci 176:42–44

    Article  CAS  PubMed  Google Scholar 

  142. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G (2000) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55:1714–1718

    Article  CAS  PubMed  Google Scholar 

  143. Wiendl H, Neuhaus O, Kappos L, Hohlfeld R (2000) Multiple Sklerose: Aktuelle Übersicht zu fehlgeschlagenen and abgebrochenen Therapiestudien. Nervenarzt 71:597–610

    Article  CAS  PubMed  Google Scholar 

  144. Arnason BGW, Jacobs G, Hanlon M et al. (1999) TNF neutralization in MS - Results of a randomized, placebo controlled multicenter study. Neurology 53:457–465

    Article  CAS  Google Scholar 

  145. van Oosten BW, Barkhof F, Truyen L et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531–1534

    Article  PubMed  Google Scholar 

  146. Calabresi PA, Fields NS, Maloni HW et al. (1998) Phase-1 trial of transforming-growth-factor-beta-2 in chronic progressive MS. Neurology 51:289–292

    Article  CAS  PubMed  Google Scholar 

  147. Noseworthy JH, Wolinsky JS, Lublin FD et al. (2000) Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 54:1726–1733

    Article  CAS  PubMed  Google Scholar 

  148. Wolinsky JS, Narayana PA, Noseworthy JH et al. (2000) Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 54:1734–1741

    Article  CAS  PubMed  Google Scholar 

  149. Kappos L, Radu EW, Dellas S et al. (1996) Deoxyspergualine in the treatment of active MS: final analysis of the European multicenter study. Neurology 46:A410–A411

    Google Scholar 

  150. Noseworthy JH, O’Brien P, Erickson BJ et al. (1998) The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 51:1342–1352

    Article  CAS  PubMed  Google Scholar 

  151. Weiner HL, Mackin GA, Matsui M et al. (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259:1321–1324

    Article  CAS  PubMed  Google Scholar 

  152. Panitch H, Francis G, and the Oral Myelin Study Group (1997) Clinical results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis [abstract]. Ann Neurol 42:459

    Google Scholar 

  153. Francis G, Evans A, Panitch H (1997) MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis [abstract]. Ann Neurol 42:467

    Google Scholar 

  154. Bielekova B, Goodwin B, Richert N et al. (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6:1167–1175

    Article  CAS  PubMed  Google Scholar 

  155. Kappos L, Comi G, Panitch H et al. (2000) Induction of a non-encephalitogenic type 2 T-helper cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, randomized phase II trial. Nat Med 6:1176–1182

    Article  CAS  PubMed  Google Scholar 

  156. Goodkin DE, Shulman M, Winkelhake J et al. (2000) A phase I trial of solubilized DR2:MBP84–102 (AG284) in multiple sclerosis. Neurology 54:1414–1420

    Article  CAS  PubMed  Google Scholar 

  157. Medaer R, Stinissen P, Truyen L, Raus J, Zhang J (1995) Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet 346:807–808

    Article  CAS  PubMed  Google Scholar 

  158. Vandenbark AA, Chou YK, Whitham R et al. (1996) Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nature Medicine 2:1109–1115

    Article  CAS  PubMed  Google Scholar 

  159. Weinshenker BG, Bass B, Karlik S, Ebers GC, Rice GP (1991) An open trial of OKT3 in patients with multiple sclerosis. Neurology 41:1047–1052

    Article  CAS  PubMed  Google Scholar 

  160. van Oosten BW, Lai M, Barkhof F et al. (1996) A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Mult Scler 1:339–342

    PubMed  Google Scholar 

  161. Rostami AM, Sater RA, Bird SJ et al. (1999) A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis. Multiple Sclerosis 5:198–203

    CAS  PubMed  Google Scholar 

  162. Baumhackl U, Mertin J, Kappos L et al. (2001) Theme European Study on Enzyme Therapy in Multiple Sclerosis (ESEMS). J Neurol 248:II/64

    Google Scholar 

  163. Smith PF (2002) Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr Opin Investig Drugs 3:859–864

    CAS  PubMed  Google Scholar 

  164. Gbadamosi J, Buhmann C, Moench A, Heesen C (2001) Failure of ondansetron in treating cerebellar tremor in MS patients - an open-label pilot study. Acta Neurol Scand 104:308–311

    Article  CAS  PubMed  Google Scholar 

  165. Zimmermann C, Hohlfeld R (1999) Fatigue bei multipler Sklerose. Nervenarzt 70:566–574

    Article  CAS  PubMed  Google Scholar 

  166. Krupp LB, Coyle PK, Doscher C et al. (1995) Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and plazebo. Neurology 45:1956–1961

    Article  CAS  PubMed  Google Scholar 

  167. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Naga-raja HN (2002) Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72:179–183

    Article  CAS  PubMed  Google Scholar 

  168. Gillson G, Richard TL, Smith RB, Wright JV (2002) A double-blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis. Mult Scler 8:30–35

    CAS  PubMed  Google Scholar 

  169. Wingerchuk DM, Benarroch EE, O’Brien PC et al. (2002) Aspirin for multiple sclerosis-related fatigue: Results of a double-blind, placebo-controlled study. Neurology 58 (Suppl 493):A492

    Google Scholar 

  170. Bever CT Jr (1994) The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol 36:S118–121

    Article  PubMed  Google Scholar 

  171. Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C (2001) Aminopyridines for symptomatic treatment in multiple sclerosis (Cochrane Review). Cochrane Database Syst Rev, p 4

    Google Scholar 

  172. Bever CT Jr, Young D, Anderson PA et al. (1994) The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44: 1054–1059

    Article  PubMed  Google Scholar 

  173. Dieterich M, Jahn K (2001) Diagnostik and Therapie von Augenmotilitätsstörungen. In: Zettl UK, Mix E (eds) Multiple Sklerose: kausalorientierte, symptomatische and rehabilitative Therapie. Springer, Heidelberg, pp 121–134

    Google Scholar 

  174. Starck M, Albrecht H, Pollmann W, Straube A, Dieterich M (1997) Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol 244:9–16

    Article  CAS  PubMed  Google Scholar 

  175. Averbuch-Heller L, Tusa RJ, Fuhry L et al. (1997) A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 41:818–825

    Article  CAS  PubMed  Google Scholar 

  176. Ostermann PO, Westerberg CE (1975) Paroxysmal attacks in multiple sclerosis. Brain 98:189–202

    Article  CAS  PubMed  Google Scholar 

  177. Rao SM, Leo GJ, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685691

    Google Scholar 

  178. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41:692–696

    Article  CAS  PubMed  Google Scholar 

  179. Plohmann AM, Kappos L, Ammann W et al. (1998) Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 64:455–462

    Article  CAS  PubMed  Google Scholar 

  180. Kraft GH (1999) Rehabilitation still the only way to improve function in multiple sclerosis. Lancet 354:2016–2017

    Article  CAS  PubMed  Google Scholar 

  181. Freeman JA, Langdon DW, Hobart JC, Thompson AJ (1997) The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 42:236–244

    Article  CAS  PubMed  Google Scholar 

  182. Solari A, Filippini G, Gasco P et al. (1999) Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 52:57–62

    Article  CAS  PubMed  Google Scholar 

  183. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 339:285–291

    Article  CAS  PubMed  Google Scholar 

  184. Sibley WA, Bamford CR, Clark K (1985) Clinical viral infections and multiple sclerosis. Lancet 1:1313–1315

    Article  CAS  PubMed  Google Scholar 

  185. De Keyser J, Zwanikken C, Boon M (1998) Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 159:51–53

    Article  PubMed  Google Scholar 

  186. Miller AE, Morgante LA, Buchwald LY et al. (1997) A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48:312–314

    Article  CAS  PubMed  Google Scholar 

  187. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S (2001) Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 344:319–326

    Article  CAS  PubMed  Google Scholar 

  188. Moriabadi NF, Niewiesk S, Kruse N et al. (2001) Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 56:938–943

    Article  CAS  PubMed  Google Scholar 

  189. De Keyser J (1998) Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection 26:319

    Article  PubMed  Google Scholar 

  190. Zipp F, Weil JG, Einhaupl KM (1999) No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 5:964–965 [letter]

    Google Scholar 

  191. Ascherio A, Zhang SM, Hernan MA et al. (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344:327–332

    Article  CAS  PubMed  Google Scholar 

  192. Baumhackl U, Franta C, Retzl J, Salomonwitz E, Eder G (2003) A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis: clinical, immunological and MRI results. Vaccine 12(S1):S56–S61

    Article  Google Scholar 

  193. Olafsson E, Hauser WA (1999) Prevalence of epilepsy in rural Iceland: a population-based study. Epilepsia 40:1529–1534

    Article  CAS  PubMed  Google Scholar 

  194. Olafsson E, Benedikz J, Hauser WA (1999) Risk of epilepsy in patients with multiple sclerosis: a population-based study in Iceland. Epilepsia 40:745–747

    Article  CAS  PubMed  Google Scholar 

  195. Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW (1996) Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 39:432–441

    Article  CAS  PubMed  Google Scholar 

  196. Winterholler M, Erbguth F, Neundorfer B (1997) The use of alternative medicine by multiple sclerosis patients - patient characteristics and patterns of use. Fortschr Neurol Psychiatr 65:555–561

    Article  CAS  PubMed  Google Scholar 

  197. Schwartz CE, Laitin E, Brotman S, LaRocca N (1999) Utilization of unconventional treatments by persons with MS: is it alternative or complementary? Neurology 52:626–629

    Article  CAS  PubMed  Google Scholar 

  198. Weilbach FX, Rieckmann P, Gold R, Toyka KV (2001) Multiple Sklerose: Kritische Betrachtung umstrittener and komplementärmedizinischer Therapien auf der Grundlage aktueller Hypothesen zur Pathogenese. Aktuelle Neurologie 28:31–38

    Article  Google Scholar 

  199. Kobelt G, Lindgren P, Smala A, Rieckmann P Group (2001) Costs and Quality of Life in Multiple Sclerosis. An observational study in Germany. Health Economics in Prevention and Care 2:60–68

    Google Scholar 

Download references

Authors
  1. H. Wiendl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurologische Universitätsklinik, Kantonsspital Basel, Petersgraben 4, Basel, 4031, Schweiz

    Andreas J. Steck

  2. Neurologische Klinik, Universitätsklinikum Düsseldorf, Moorenstraße 5, Düsseldorf, 40225, Deutschland

    Hans-Peter Hartung  & Bernd C. Kieseier  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Wiendl, H. (2003). Behandlung der multiplen Sklerose. In: Steck, A.J., Hartung, HP., Kieseier, B.C. (eds) Demyelinisierende Erkrankungen. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57441-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57441-2_14

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-63265-5

  • Online ISBN: 978-3-642-57441-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation